Day Gain | ||
Gain | ||
Market Val | ||
Costs | ||
Cash | ||
Portfolio | ||
Realized | ||
Dividend |
Date | For | Estimate | Reported | Surprise | surprise % |
---|---|---|---|---|---|
2024-11-07 | 2024-09 | 4.53 | N/A | N/A | N/A |
2024-08-08 | 2024-06 | 2.64 | 3.92 | 1.28 | 48.48% |
2024-04-30 | 2024-03 | 2.53 | 2.58 | 0.05 | 1.98% |
2024-02-06 | 2023-12 | 2.47 | 2.49 | 0.02 | 0.81% |
2023-11-02 | 2023-09 | -0.08 | 0.1 | 0.18 | 225.00% |
2023-08-08 | 2023-06 | 1.98 | 2.11 | 0.13 | 6.57% |
Date | Firm | Action | From | To |
---|---|---|---|---|
2023-10-10 | Morgan Stanley | Upgrade | Overweight | Overweight |
2023-10-08 | Wells Fargo | Upgrade | Overweight | Overweight |
2023-10-08 | Cantor Fitzgerald | Upgrade | Overweight | Overweight |
2023-10-01 | Cantor Fitzgerald | Upgrade | Overweight | Overweight |
2023-09-04 | Cantor Fitzgerald | Upgrade | Overweight | Overweight |
2023-09-04 | Morgan Stanley | Upgrade | Overweight | Overweight |
Date | Name | Relation | Quantity | Description |
---|---|---|---|---|
2024-09-15 | ALVAREZ RALPH | Director | 54.25K | Stock Award(Grant) |
2024-08-11 | HAKIM ANAT | General Counsel | 30.48K | Stock Gift |
2024-09-15 | HEDLEY MARY LYNNE | Director | 1.64K | Stock Award(Grant) |
2024-09-15 | JOHNSON KIMBERLY H | Director | 2.69K | Stock Award(Grant) |
2024-09-02 | LILLY ENDOWMENT, INC. | Beneficial Owner of more than 10% of a Class of Security | 96.89M | Sale |
2024-09-15 | LUCIANO JUAN R | Director | 15.81K | Stock Award(Grant) |
Report Date | Organization | Position | Value | Percentage |
---|---|---|---|---|
2023-09-29 | Lilly Endowment, Inc | 99.98M | 53.70B | 10.53% |
2023-06-29 | Vanguard Group Inc | 69.92M | 32.79B | 7.37% |
2023-06-29 | Blackrock Inc. | 64.45M | 30.23B | 6.79% |
2023-06-29 | PNC Financial Services Group, Inc. | 51.87M | 24.33B | 5.46% |
2023-06-29 | State Street Corporation | 33.88M | 15.89B | 3.57% |
2023-06-29 | FMR, LLC | 32.80M | 15.38B | 3.46% |
Report Date | Organization | Position | Value | Percentage |
---|---|---|---|---|
2023-06-29 | Vanguard Total Stock Market Index Fund | 26.65M | 12.50B | 2.81% |
2023-06-29 | Vanguard 500 Index Fund | 18.76M | 8.80B | 1.98% |
2023-06-29 | Vanguard/Primecap Fund | 13.35M | 6.26B | 1.41% |
2023-05-30 | Fidelity 500 Index Fund | 8.83M | 3.79B | 0.93% |
2023-08-30 | SPDR S&P 500 ETF Trust | 8.68M | 4.81B | 0.91% |
2023-08-30 | iShares Core S&P 500 ETF | 7.37M | 4.08B | 0.78% |
Dividend | Date |
---|---|
1.3 | 2024-08-15 |
1.3 | 2024-05-15 |
1.3 | 2024-02-15 |
1.3 | 2024-02-14 |
1.13 | 2023-11-14 |
1.13 | 2023-09-08 |
Split | Date |
---|---|
2 : 1 | 1997-10-16 |
2 : 1 | 1995-12-21 |
2 : 1 | 1989-05-01 |
2 : 1 | 1986-01-30 |
-
-
-
$LLY Competition in weight loss years away.
Over blown. Viking is too small to distribute well. -
$LLY Approvals left and right! Best of Breed!
-
What’s everyone gonna do when $LLY comes out with their pill form and it’s the 2nd generation of an improved formulation? I believe Roche had a study of 6 people in it. Be grateful for this absolute destruction as it gives the opportunity to load up on the greatest pharmaceutical company that’s yet to see its full potential. They are sitting on massive war chest to be used for R&D and acquisitions.
-
everyone start making SEC reports… theyll eventually have to pass word to them to chill it out
-
$LLY Barclays expects Eli Lilly to beat earnings, gain nearly 10%
Investors should pick up shares of Eli Lilly as the drugmaker looks well-positioned heading into earnings season, according to Barclays.
Analyst Carter Gould kept his overweight rating and raised his price target by $112 to $1,025, which implies a roughly 9.9% potential increase for the stock.
Gould is bullish on Eli Lilly ahead of its quarterly results due on Aug. 8, saying he sees an attractive set-up for the stock and expects the company to beat analysts’ high consensus expectations.
“We expect a strong Mounjaro print (+$71mn vs. cons) and in-line Zepbound numbers (+64% q/q), but see room for the company to raise guidance again – and progress ex- Obesity (i.e., Kisunla) adds a new dimension that was lacking over most of ’23-’24,” Gould said in a Wednesday note.
He added he expects increasing appreciation and focus on the “disruptive effect” of Orforglipron, an oral nonpeptide GLP-1 receptor agonist, on the company’s current share dynamics.
This year, Eli Lilly shares have advanced nearly 60%.
-
why does everyone think a split is bullish?
Every stock that has split never saw another new high after
-
$LLY Oversold. We are just fine.
-
$LLY Sleepy Joe Biden Bones us again
-
$LLY FDA Approves Donanemab, Eli Lilly’s treatment for early Alzheimer’s disease
-
$LLY Listen to the Sad BearTard Blather
-
$LLY Pied Piper has lost All Credibility.
Downgrade to hold with a$400+ price target?
Total joke. Piper lowered to buy lower.
This is a Best of Breed Company going much higher -
$LLY People, look at it as a gift. Buy the dip.
Biden won’t be around long enough to do anything -
$LLY Eli Lilly expects FDA decision on weight loss drug Zepbound for sleep apnea as early as end of the year
-
ResMed stock cut at Wolfe on Lilly GLP-1 threat (NYSE:RMD)
news.google.com • -
December 20th Options Now Available For Eli Lilly (LLY)
news.google.com • -
Eli Lilly (LLY) Stock Price Prediction and Forecast 2025-2030
news.google.com • -
Eli Lilly Stock Up 21% in 6 Months: Time to Add to Your Portfolio?
news.google.com • -
Looking Into Eli Lilly's Recent Short Interest
news.google.com • -
Eli Lilly Stock Up 21% in 6 Months: Time to Add to Your Portfolio?
news.google.com • -
Eli Lilly Stock Up 21% in 6 Months: Time to Add to Your Portfolio?
news.google.com • -
Is Most-Watched Stock Eli Lilly and Company (LLY) Worth Betting on Now?
news.google.com • -
Eli Lilly (LLY) Stock Price Prediction and Forecast 2025-2030
news.google.com • -
Lilly Gets FDA Approval for Eczema Drug Ebglyss
zacks.com • -
Morgan Stanley’s Best Stock Picks: 15 Stocks To Own For 2025
news.google.com • -
(LLY) Long Term Investment Analysis
news.google.com • -
Do queasy side effects mean the end of weight-loss drug stock hype?
news.google.com • -
Is Eli Lilly and Company (LLY) an Unstoppable Dividend Stocks to Buy?
news.google.com • -
Eli Lilly and Co (LLY) Stock Price, Trades & News
news.google.com • -
Eli Lilly stock gains as Citi resumes at buy (NYSE:LLY)
news.google.com • -
Eli Lilly (LLY) Stock Price Prediction and Forecast 2025-2030
news.google.com • -
NVO Oral Obesity Pill Tops Wegovy; LLY, VKTX, GPCR Stocks Rise
news.google.com • -
Bull of the Day: Eli Lilly (LLY)
news.google.com •